The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

In this interview, industry expert Dr. Lohit Khera discusses the evolving role of microRNA in research, diagnostics, and ...

Fusobacteria, which are part of the oral microbiome, are suspected of playing a role in cancer progression. Scientists at the ...

The study, published in the journal Nucleic Acids Research, concerns a previously unknown strategy ... The protein, referred ...

Inc. Creyon Bio is a nucleic acid drug development company whose goal is to make oligonucleotide (oligo) therapies safer and more effective for patients with rare and common diseases. The company is ...

Mana.bio, a biotechnology company leveraging artificial intelligence (AI) and nanotechnology for targeted RNA delivery, today announced three poster presentations at the American Society of Gene & ...

Return on Equity (ROE): Co-Diagnostics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -18.68%, the company showcases efficient use ...

Fusobacteria, which are part of the oral microbiome, are suspected of playing a role in cancer progression. Scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) are working on ...

Fusobacteria, part of the oral microbiome, are suspected of playing a role in cancer progression. Scientists are working on ...

Scientists develop RNA-based technology to combat plant viruses, enhancing crop immunity and reducing losses worldwide.

The treatment, which aimed to block production of a mutant protein, reduced the frequency of infant’s seizures, but did not ...